In the project also participate the IRYCIS Aptamer Group, led by Dr. Víctor M. González and M. Elena Martín, the Neurovascular Research Unit, directed by professors Ignacio Lizasoain and María Ángeles Moro and belonging to the University Institute of Research in Neurochemistry of the Madrid Complutense University and the Health Research Institute Hospital 12 de Octubre (i + 12) of Madrid, the Neurovascular Research Group of the Institute of Biomedicine of Seville (IBiS) and the biopharmaceutical company AptaTargets SL, participated by Aptus, dedicated to the preclinical and clinical development of innovative molecules based on aptamer technology. The work has recently been published in Molecular Therapy.